PNC Financial Services Group Inc. Reduces Stake in Becton, Dickinson and Company $BDX

PNC Financial Services Group Inc. lowered its stake in Becton, Dickinson and Company (NYSE:BDX) by 3.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 168,120 shares of the medical instruments supplier’s stock after selling 5,758 shares during the quarter. PNC Financial Services Group Inc. owned approximately 0.06% of Becton, Dickinson and Company worth $32,627,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Activest Wealth Management lifted its stake in Becton, Dickinson and Company by 285.3% in the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 97 shares in the last quarter. Imprint Wealth LLC purchased a new stake in Becton, Dickinson and Company in the 3rd quarter valued at approximately $25,000. Steph & Co. lifted its stake in Becton, Dickinson and Company by 95.6% in the 4th quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 65 shares in the last quarter. WPG Advisers LLC lifted its stake in Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 61 shares in the last quarter. Finally, Accredited Wealth Management LLC lifted its stake in Becton, Dickinson and Company by 77.8% in the 3rd quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 70 shares in the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the topic of a number of recent research reports. Argus reduced their target price on Becton, Dickinson and Company from $230.00 to $180.00 and set a “buy” rating on the stock in a research note on Monday, March 23rd. Stifel Nicolaus reduced their target price on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Piper Sandler reduced their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Royal Bank Of Canada set a $175.00 target price on Becton, Dickinson and Company in a research note on Tuesday, April 14th. Finally, Citigroup reduced their target price on Becton, Dickinson and Company from $233.00 to $232.00 and set a “buy” rating on the stock in a research note on Tuesday, February 10th. Seven analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $184.86.

Becton, Dickinson and Company Trading Down 0.3%

Shares of Becton, Dickinson and Company stock opened at $146.45 on Friday. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $187.35. The firm has a market cap of $40.35 billion, a PE ratio of 37.08, a P/E/G ratio of 10.40 and a beta of 0.22. The business’s fifty day moving average is $153.14 and its two-hundred day moving average is $178.28. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the prior year, the company posted $3.35 EPS. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Analysts anticipate that Becton, Dickinson and Company will post 12.61 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be paid a dividend of $1.05 per share. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Becton, Dickinson and Company announced that its board has approved a share repurchase program on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.